Business Daily from THE HINDU group of publications
Friday, Jul 21, 2006
Business Daily from THE HINDU group of publications Friday, Jul 21, 2006 |
|
|
|
|
|
|
|
Corporate
-
Alliances & Joint Ventures
Our Bureau
New Delhi , July 20 Ranbaxy Laboratories has said it has signed a licensing agreement with Canada's Janssen-Ortho Inc to market the generic version of Risperidone, a drug for psychotic disorders, in Canada. "This agreement will provide Ranbaxy with an opportunity to commercialise products that have been shown to have a favourable impact on patients and allow Ranbaxy to reinforce its presence in Canada," Mr Bill Abboud, President of Ranbaxy Pharmaceuticals Canada Inc (RPCI), a unit of Ranbaxy Laboratories, said in a statement. The drug will be manufactured by Janssen, the Ranbaxy statement said. The generic version of Risperidone is sold under Ranbaxy's label, Ran Risperidone, it said, adding that the Canadian patent for Risperidone expired in July and Ran Risperidone is now available through pharmacies and wholesalers, it added. RPCI is a wholly owned subsidiary of the company and is engaged in the sale and distribution of generic medicines in the Canadian healthcare system.
More Stories on : Alliances & Joint Ventures | Pharmaceuticals | Ranbaxy Laboratories Ltd
Article E-Mail :: Comment :: Syndication :: Printer Friendly Page
|
Stories in this Section |
|
The Hindu Group: Home | About Us | Copyright | Archives | Contacts | Subscription Group Sites: The Hindu | Business Line | Sportstar | Frontline | The Hindu eBooks | The Hindu Images | Home |
Copyright © 2006, The
Hindu Business Line. Republication or redissemination of the contents of
this screen are expressly prohibited without the written consent of
The Hindu Business Line
|